MENU
+Compare
GNPX
Stock ticker: NASDAQ
AS OF
Jan 15, 10:48 AM (EDT)
Price
$3.05
Change
+$0.18 (+6.27%)
Capitalization
6.54M

GNPX Genprex Inc. Forecast, Technical & Fundamental Analysis

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes... Show more

GNPX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for GNPX with price predictions
Jan 14, 2026

GNPX's RSI Oscillator ascends from oversold territory

The RSI Indicator for GNPX moved out of oversold territory on January 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 46 similar instances when the indicator left oversold territory. In of the 46 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 08, 2026. You may want to consider a long position or call options on GNPX as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +3 3-day Advance, the price is estimated to grow further. Considering data from situations where GNPX advanced for three days, in of 201 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNPX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GNPX broke above its upper Bollinger Band on January 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for GNPX entered a downward trend on January 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.518) is normal, around the industry mean (27.929). P/E Ratio (0.087) is within average values for comparable stocks, (51.397). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.899). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.547).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. GNPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
GNPX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of molecular therapies for cancer treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
3300 Bee Cave Road
Phone
+1 877 774-4679
Employees
26
Web
https://www.genprex.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SII112.754.13
+3.80%
Sprott
GPUS0.32N/A
+1.49%
Hyperscale Data Inc
NRIM27.840.11
+0.40%
Northrim BanCorp
RDHL1.23-0.01
-0.81%
Redhill Biopharma Ltd
BURL303.36-6.94
-2.24%
Burlington Stores

GNPX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GNPX has been loosely correlated with NERV. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GNPX jumps, then NERV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNPX
1D Price
Change %
GNPX100%
+19.58%
NERV - GNPX
64%
Loosely correlated
+0.94%
TOVX - GNPX
49%
Loosely correlated
-4.88%
OMER - GNPX
48%
Loosely correlated
+3.65%
REVB - GNPX
48%
Loosely correlated
-0.57%
RXRX - GNPX
31%
Poorly correlated
+3.41%
More